首页> 美国卫生研究院文献>Journal of Neurophysiology >Anatomical localization of Cav3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys
【2h】

Anatomical localization of Cav3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys

机译:MPTP处理的猴子的运动丘脑中Cav3.1钙通道的解剖定位和T型钙通道阻滞的电生理作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Conventional anti-Parkinsonian dopamine replacement therapy is often complicated by side effects that limit the use of these medications. There is a continuing need to develop nondopaminergic approaches to treat Parkinsonism. One such approach is to use medications that normalize dopamine depletion-related firing abnormalities in the basal ganglia-thalamocortical circuitry. In this study, we assessed the potential of a specific T-type calcium channel blocker (ML218) to eliminate pathologic burst patterns of firing in the basal ganglia-receiving territory of the motor thalamus in Parkinsonian monkeys. We also carried out an anatomical study, demonstrating that the immunoreactivity for T-type calcium channels is strongly expressed in the motor thalamus in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. At the electron microscopic level, dendrites accounted for >90% of all tissue elements that were immunoreactive for voltage-gated calcium channel, type 3.2-containing T-type calcium channels in normal and Parkinsonian monkeys. Subsequent in vivo electrophysiologic studies in awake MPTP-treated Parkinsonian monkeys demonstrated that intrathalamic microinjections of ML218 (0.5 μl of a 2.5-mM solution, injected at 0.1–0.2 μl/min) partially normalized the thalamic activity by reducing the proportion of rebound bursts and increasing the proportion of spikes in non-rebound bursts. The drug also attenuated oscillatory activity in the 3–13-Hz frequency range and increased gamma frequency oscillations. However, ML218 did not normalize Parkinsonism-related changes in firing rates and oscillatory activity in the beta frequency range. Whereas the described changes are promising, a more complete assessment of the cellular and behavioral effects of ML218 (or similar drugs) is needed for a full appraisal of their anti-Parkinsonian potential.
机译:常规的抗帕金森氏症多巴胺替代疗法通常因副作用而变得复杂,这些副作用限制了这些药物的使用。持续需要开发非多巴胺能疗法来治疗帕金森氏病。一种这样的方法是使用使基底神经节-丘脑皮质回路中多巴胺消耗相关的放电异常正常化的药物。在这项研究中,我们评估了一种特定的T型钙通道阻滞剂(ML218)消除帕金森氏猴中运动丘脑基底神经节接收区域内触发的病理性放电发作的潜力。我们还进行了一项解剖学研究,表明在正常和1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的运动丘脑中,T型钙通道的免疫反应性强烈表达猴子。在电子显微镜下,树突状细胞占正常和帕金森氏猴中对电压门控钙通道,含3.2型T型钙通道免疫反应的所有组织元素的> 90%。随后在清醒的MPTP处理的帕金森氏猴中进行的体内电生理研究表明,丘脑内注射ML218(0.5μl的2.5mM溶液,以0.1–0.2μl/ min的速度注射)通过减少反弹爆发的比例和恢复部分丘脑活性而实现了正常。增加非反弹爆发中的峰值比例。该药物还减弱了3-13 Hz频率范围内的振荡活动,并增加了伽马频率振荡。但是,ML218未能使β频率范围内帕金森氏症相关的射击频率和振荡活动变化正常化。尽管所描述的变化是有希望的,但需要对ML218(或类似药物)的细胞和行为效应进行更全面的评估,以全面评估其抗帕金森氏潜能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号